Ignite Creation Date:
2025-12-24 @ 5:40 PM
Ignite Modification Date:
2026-04-18 @ 11:28 PM
Study NCT ID:
NCT02440568
Status:
TERMINATED
Last Update Posted:
2021-07-06
First Post:
2015-05-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
Sponsor:
University of Illinois at Chicago
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-06-05
Start Date Type:
ACTUAL
Primary Completion Date:
2018-11-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-11-30
Completion Date Type:
ACTUAL
First Submit Date:
2015-05-07
First Submit QC Date:
None
Study First Post Date:
2015-05-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-11-16
Results First Submit QC Date:
None
Results First Post Date:
2021-07-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-01
Last Update Post Date:
2021-07-06
Last Update Post Date Type:
ACTUAL